MedTrace Logo

Exploring Biomarkers Predicting the Outcome of Acute-on-chronic Liver Failure

NCT02965560 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2018-06-06

No results posted yet for this study

Summary

Acute-on-chronic liver failure (ACLF) is an ailment with high incidence of multiorgan failure (MOF) and consequent mortality. Systemic inflammation and susceptibility to infection are characteristic pathophysiological features. Prostaglandin E2 (PGE2) could subdue systemic inflammation and alleviate liver injury in mice model. However, there are no studies evaluating PGE2 as a predictor of early mortality.This study is designed to investigate whether plasma PGE2 and its receptors are associated with development of MOF and predict short-term mortality in patients with acute-on-chronic liver failure. By the way, we will also measure several other potential predictive factors (C-reactive protein,severe hyponatremia, Second infections,Diabetes mellitus,High density lipoprotein,interleukin-10,serum bile acids,ferritin,the neutrophil to lymphocyte ratio,soluable urokinase plasminogen activator receptor,vWF-Ag levels and FVIII-to-PC ratios).

Conditions

  • Acute-On-Chronic Liver Failure
  • Cirrhosis and Chronic Liver Disease

Interventions

DIAGNOSTIC_TEST

plasma suPAR, PGE2 measurement. Other biomarkers were just recorded from clinical laboratory.

Sponsors & Collaborators

  • First Affiliated Hospital of Zhejiang University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-10
Primary Completion
2017-10-10
Completion
2018-06-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02965560 on ClinicalTrials.gov